CR11361A - Moleculas y metodos para modular el componente de complemento - Google Patents

Moleculas y metodos para modular el componente de complemento

Info

Publication number
CR11361A
CR11361A CR11361A CR11361A CR11361A CR 11361 A CR11361 A CR 11361A CR 11361 A CR11361 A CR 11361A CR 11361 A CR11361 A CR 11361A CR 11361 A CR11361 A CR 11361A
Authority
CR
Costa Rica
Prior art keywords
methods
modulate
molecules
complement component
compositions
Prior art date
Application number
CR11361A
Other languages
English (en)
Inventor
Bijan Etemad-Gilbertson
Braydon Charles Guild
Mark Taylor Keating
Young-In Kim
Lloyd B Klickstein
Dmitri Mikhailov
Mariusz Milik
Michael Roguska
Igor Splawski
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR11361A publication Critical patent/CR11361A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

En la presente se describen composiciones que se enlazan con los epitopos de C3b, y metodos para utilizar las composiciones
CR11361A 2007-11-02 2010-04-09 Moleculas y metodos para modular el componente de complemento CR11361A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98495107P 2007-11-02 2007-11-02

Publications (1)

Publication Number Publication Date
CR11361A true CR11361A (es) 2010-06-01

Family

ID=40343498

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11361A CR11361A (es) 2007-11-02 2010-04-09 Moleculas y metodos para modular el componente de complemento

Country Status (21)

Country Link
US (1) US20090175875A1 (es)
EP (1) EP2207807A2 (es)
JP (1) JP2011503024A (es)
KR (1) KR20100067681A (es)
CN (1) CN101848937A (es)
AR (1) AR069130A1 (es)
AU (1) AU2008320820A1 (es)
CA (1) CA2703911A1 (es)
CL (1) CL2008003241A1 (es)
CO (1) CO6270341A2 (es)
CR (1) CR11361A (es)
EA (1) EA201000717A1 (es)
IL (1) IL204722A0 (es)
MA (1) MA31795B1 (es)
MX (1) MX2010004833A (es)
PE (1) PE20091388A1 (es)
SV (1) SV2010003556A (es)
TN (1) TN2010000169A1 (es)
TW (1) TW200924795A (es)
WO (1) WO2009056631A2 (es)
ZA (1) ZA201002335B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2044111E (pt) 2006-06-21 2014-11-12 Univ Colorado Regents Abordagem seletiva do fator h do complemento para o tratamento de doenças
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
AU2008287426B2 (en) * 2007-08-10 2014-06-26 Protelica, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
AU2008317724B2 (en) 2007-11-02 2011-06-02 Novartis Ag Improved Nogo-A binding molecules and pharmaceutical use thereof
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
RS20120461A1 (sr) 2009-07-02 2013-06-28 Musc Foundation For Research Development Metode za stimulaciju regeneracije jetre
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
JP5986990B2 (ja) 2010-05-14 2016-09-06 ザ リージェンツ オブ ザ ユニヴァーシティ オブ コロラド，ア ボディ コーポレート 改善された補体レセプター２（ｃｒ２）ターゲティング基
MX2012014975A (es) 2010-06-22 2013-03-12 Univ Colorado Regents Anticuerpos al fragmento c3d de componente 3 de complemento.
WO2012075023A2 (en) 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
JP2015535212A (ja) 2012-08-17 2015-12-10 ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト 補体活性化を検出するための組成物および方法
SI3011345T1 (sl) 2013-08-07 2017-12-29 Alexion Pharmaceuticals, Inc. Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
EP3092252B1 (en) 2014-01-08 2019-09-18 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibody targeting cell surface deposited complement protein c3d and use thereof
WO2016033382A1 (en) * 2014-08-27 2016-03-03 Capnia, Inc. Methods for immune globulin administration
AU2016375183B2 (en) * 2015-12-23 2021-01-21 eleva GmbH Polypeptides for inhibiting complement activation
WO2017218515A1 (en) 2016-06-14 2017-12-21 Regeneron Pharmaceuticals, Inc. Anti-c5 antibodies and uses thereof
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING CENTRAL NERVOUS SYSTEM DAMAGE
MX2020006113A (es) 2017-12-13 2020-08-24 Regeneron Pharma Combinaciones de anticuerpos anti-c5 y usos de las mismas.
GB201800620D0 (en) 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN111171147B (zh) * 2020-02-11 2021-07-20 北京康普美特创新医药科技有限责任公司 一种抗补体c3分子的全人源单克隆抗体及应用
PE20250390A1 (es) 2021-12-22 2025-02-11 Boehringer Ingelheim Int Anticuerpos anti-c3 y fragmentos de union al antigeno de estos y sus usos para tratar enfermedades oftalmicas u oculares
US20240228652A9 (en) * 2022-09-20 2024-07-11 Visterra, Inc. Treatment of complement mediated diseases and disorders with c3b antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE452065B (sv) * 1986-04-11 1987-11-09 Ulf R Nilsson Antikroppspreparation vars antikroppar er specifika for determinanter i c3 b regionen hos denaturerat humant c3 samt dess anvendning och framstellning
US5932217A (en) * 1991-05-03 1999-08-03 The Rockefeller University Peptides which inhibit adhesion between leukocytes and endothelial cells
AU6397796A (en) * 1995-06-29 1997-01-30 Medical Biology Institute Method for identifying peptides that affect protein-protein interactions and complement-modulating peptides
AU2002251366A1 (en) * 2001-05-02 2002-11-11 Oxford Glycosciences (Uk) Ltd Proteins, genes and their use for diagnosis and treatment of breast cancer
US7042716B2 (en) * 2003-08-25 2006-05-09 Simon John Edward Shearman Ergonomic pull-out computer housing
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
US7327547B1 (en) * 2006-01-20 2008-02-05 Epstein Barry M Circuit element and use thereof
KR101572700B1 (ko) * 2007-06-07 2015-11-30 제넨테크, 인크. 보체-관련 장애의 예방 및 치료를 위한 Ｃ３ｂ 항체 및 방법

Also Published As

Publication number Publication date
JP2011503024A (ja) 2011-01-27
CA2703911A1 (en) 2009-05-07
AR069130A1 (es) 2009-12-30
EP2207807A2 (en) 2010-07-21
CO6270341A2 (es) 2011-04-20
WO2009056631A3 (en) 2009-08-20
SV2010003556A (es) 2011-03-23
PE20091388A1 (es) 2009-09-24
ZA201002335B (en) 2011-02-23
CN101848937A (zh) 2010-09-29
CL2008003241A1 (es) 2009-07-31
EA201000717A1 (ru) 2010-12-30
MA31795B1 (fr) 2010-10-01
TW200924795A (en) 2009-06-16
US20090175875A1 (en) 2009-07-09
MX2010004833A (es) 2010-05-27
TN2010000169A1 (en) 2011-11-11
IL204722A0 (en) 2010-11-30
WO2009056631A2 (en) 2009-05-07
KR20100067681A (ko) 2010-06-21
AU2008320820A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
SV2010003556A (es) Moleculas y metodos para modular el componente de complemento
AR066042A1 (es) Moleculas y metodos para modular la proteina convertasa-subtilisina /quexina tipo 9 (pcsk9)
CR20160206A (es) Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento C5
CO6321189A2 (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CO6680675A2 (es) Tidiazoles substituidos y composiciones pesticidas que los contienen
ECSP10010344A (es) Azolilmetiloxiranos, su uso y agentes que los contienen
MX2019008065A (es) Composiciones que comprenden anticuerpos anti-cd38 y lenalidomida.
CU20140073A7 (es) Composiciones y métodos para anticuerpos que actúan sobre el factor p
CO6450665A2 (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
AR069474A1 (es) Material anticorrosivo
CL2011000527A1 (es) Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c.
CO6741157A2 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
CR9786A (es) Compuestos de bencimidazol-tiofeno
CL2011000454A1 (es) Compuestos derivados de picolinamida, inhibidores de quinasa pim, asociada a tumorigenesis; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
AR060241A1 (es) Composiciones y metodos de uso para anticuerpos de c-met
BR112013016242A2 (pt) método de cimentação e, composição de cimentação
CO6741218A2 (es) Composición pesticida y procesos relacionados con el mismo
UY30304A1 (es) Moduladores de mglur5 i
GT201000047A (es) Mejoras en compuestos organicos o relacionadas con los mismos
CO6310993A2 (es) Moleculas utiles para el control de insectos
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
MX2009010103A (es) Composiciones estructuradas que comprenden una arcilla.
DOP2010000062A (es) Derivados de ciclopropilamida
UY30307A1 (es) Moduladores de mglur5 vi
UY30306A1 (es) Moduladores de mglur5 iii

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)